GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

The researchers found that significantly lower rates of opioid overdose and alcohol intoxication were reported in patients with GIP/GLP-1 RA prescriptions compared with those without such ...

Mohammad Ali Sheffeh, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events ...

Annual prevalence of GLP-1 RA use among US adults without diabetes increased from 0.1% in 2018-2021 to 0.4% in 2022, with an estimated 854,728 adults without diabetes taking these medications.

The median time receiving treatment was 3.9 months. The researchers found that GLP-1 RA use was associated with a lower rate of any hyperkalemia and moderate-to-severe hyperkalemia compared with ...